A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

NCT07199270 ↗

Phase 1 Recruiting 64 enrolled Genrix (Shanghai) Biopharmaceutical Co., Ltd.

RandomizedSequentialQuadruple-blindTreatment

Summary

he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups

Timeline

Start: 2025-09-18
Primary completion: 2026-09-18
Completion: 2026-12-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GR2303	Unknown	—	—

Indications

No indication recorded.